Moteur de recherche d’entreprises européennes
Financement de l’UE (3 787 933 €) : optogénétique in vivo, électrotrophiologie et phArmacologie avec une DUST ultRasonique pour la maladie de Parkinson Hor28/08/2017 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
optogénétique in vivo, électrotrophiologie et phArmacologie avec une DUST ultRasonique pour la maladie de Parkinson
The main goal of the STARDUST project is to realize a novel wireless implantable and independent micro-scale device (200x200x200 µm3) enabling in-vivo electrophysiology, optogenetics and ultra-localized drug delivery in freely moving animals. The device will be used to target specific neural circuits of the brain and test a new therapeutic approach for Parkinson’s Disease (PD). The methods used in this project are based on cutting-edge miniaturized technology combining integrated chips, microelectromechanical systems (MEMS), local drug delivery, integrated electrodes and micro-scale light emitting diodes (µLEDs). STARDUST will benefit from these advances and for the first time provide an implantable ultrasonically-powered miniaturized device for in-vivo optogenetics, local drug delivery and electrophysiological monitoring – all in one single device. The proposed device is expected to provide an output power of 1-20 mW/mm2 for optogenetics with two different wavelengths, one for neuron activation and one for triggering drug-delivery; STARDUST will provide proof of concept. The main novelty of the STARDUST project is the convergence of multiple, interdisciplinary fields including optogenetics, triggered drug-delivery, miniaturized ultrasonic energy harvesting, material science and nanoelectronics. The main ambition of the project is to develop a new technology platform to be used for future implantable in-vivo optogenetic devices for monitoring and treating diseases, with an optional local drug delivery add-on beyond 2025. Establishing proof of concept of the STARDUST platform will be the foundation for other applications within photodynamic therapy such as cancer treatment and other neurological and non-neurological disorders.
| Aarhus Universitet | 1 072 789 € |
| Biomodics ApS | 485 736 € |
| Centre National de la Recherche Scientifique CNRS | 592 855 € |
| Fraunhofer Gesellschaft ZUR Forderung DER Angewandten Forschung e. V. | 375 121 € |
| Humboldt-Universitaet ZU Berlin | 356 000 € |
| Spinverse AB | 0,00 € |
| Spinverse Oy | 171 623 € |
| Universidade Federal do Pará | 60 500 € |
| University College Cork - National University of Ireland, Cork | 360 514 € |
| VIB VZW | 312 794 € |
https://cordis.europa.eu/project/id/767092
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
